fluorine-fluoro-2-deoxy-D-glucose (FDG) on 55 patients with tumours involving the musculoskeletal system in order to evaluate its role in operative planning. The standardised uptake value (SUV) of FDG was calculated and, to distinguish malignancies from benign lesions, the cases were divided into high (≥ 1.9) and low (< 1.9) SUV groups.
The evaluation of many bone and soft-tissue masses before operation remains a diagnostic dilemma for orthopaedic surgeons. Although CT and/or MRI give excellent detail regarding anatomical localisation and heterogeneity, they are not sufficiently reliable to distinguish the malignancy or biological activity of tumour cells. 1, 2 Tumour tissues generally show enhanced glycolysis, 3 and this has prompted investigators to use 18 fluorine-fluoro-2-deoxy-2-D-glucose (FDG) as an imaging agent in conjunction with positron emission tomography (PET), 4, 5 particularly in the evaluation of primary brain tumours, 6 but also for distinguishing between other types of lesion such as pancreatic carcinoma and mass-forming pancreatitis. 7 The standardised uptake value (SUV) calculated with FDG can be used as a prognostic factor for pancreatic carcinoma. 8 Several investigators have shown that there is a relationship between the uptake of FDG and the histopathological grade in musculoskeletal tumours. [9] [10] [11] This is useful for detecting recurrent or residual sarcomas. [12] [13] [14] Griffeth et al 15 suggested that FDG-PET may be a useful adjunct in the preoperative evaluation of soft-tissue tumours. We have investigated the use of FDG-PET imaging for the quantitative and qualitative evaluation of musculoskeletal tumours and found a higher uptake in metastatic lesions. The role of phosphohexose isomerase (PHI) in the possible molecular mechanisms underlying the high uptake was studied since PHI is a key enzyme of glycolytic metabolism related to accumulation of FDG within tissue. 16 It has recently been found to act as an autocrine motility factor (AMF), 17 which is important for metastasis. [18] [19] [20] [21] Patients and Methods
We performed FDG-PET in 55 patients (26 men and 29 women) with a mean age of 45.3 years (12 to 77) who had been referred for the clinical evaluation of bone and softtissue tumours. There were 59 lesions; 18 were in bone, 35 in soft tissues, four were metastatic and two were postoperative scars. Two were recurrent tumours (Tables I to  III) . In one patient (case 56) an extraskeletal osteosarcoma in the foot was resected widely but pulmonary metastases developed which were then evaluated. In two patients who had bone metastases from pancreatic (case 2) and prostatic
PET activity
Injected dose/body weight SUV = carcinoma (case 4) additional metastatic lesions were discovered and were also included in the analysis. In two patients (cases 54 and 55) a malignant fibrous histiocytoma (MFH) and an angiosarcoma developed in the thigh and hand, respectively. These resected areas were evaluated one year after the operation and were depicted as postoperative scars (Table II) . No recurrent lesions were found after several months. All patients had previously had routine evaluation by CT, MRI and/or angiography either at our hospital or at referring institutions. The final diagnosis was established by biopsy, surgical excision or at postmortem for all patients except for one with a benign lesion (case 32) who was considered to have a haematoma on the basis of clinical and radiological criteria. PET imaging. FDG was produced in the cyclotron facility at Gunma University as has been described previously, 22 and 18 F-alpha-methyl tyrosine (F-FMT) synthesised using the method developed by Tomiyoshi et al. 23 Before the PET study, patients fasted for at least four hours, at which time the normal glucose levels were confirmed by clinical laboratory tests. 24 PET was performed using a whole-body PET where PET activity is a calibrated uptake measured in millicuries per millilitre, as described previously.
24
RNA extraction, reverse transcription, and polymerase chain-reaction amplification (PCR) of PHI. Total cellular RNA was isolated from 500 mg samples (wet weight) using Isogen (Nippongene, Toyama, Japan) based on a standard procedure with phenol-chloroform extraction. To avoid contamination of genomic DNA, DNAse I treatment was performed before cDNA synthesis according to Maniatis, Fritsch and Sambrook. 25 The cDNA was synthesised by reverse transcriptase from the total RNA using random hexomers of a first-stranded cDNA synthesis kit (Pharmacia, Uppsala, Sweden). Oligonucleotide primers were designed to contain the PHI/AMF open reading frame of the mRNA sequence, as described previously. 20 The sequences were as follows: sense (5-CGCCATGGCC-GCTCTCACC) and antisense (5-CGAGAAGAGAAA-GGGGAG), which corresponds to nucleotides -4 to +15 and +1708 to +1725, respectively. The PCR conditions were as follows: 94°C for 10 minutes as an initial denaturation, 30 cycles or cycles as indicated of 94°C for 30 seconds, 55°C for 30 seconds and 72°C for two minutes, and 72°C for ten minutes as a final extension. The PCR products, expected to be 1729 bp in size, were analysed by 1% agarose gel electrophoresis and ethidium bromide staining. Expression of the human S14 ribosomal protein was analysed as an internal control with a 143 bp PCR product: 26 Tables I and II , respectively. There was no correlation between SUV and size of the mass, but estimates of SUV confirmed qualitative visual assessment of separation into benign, primary malignant and metastatic groups. There was a highly significant difference (p < 0.0001) between benign and malignant lesions. No malignant tumours had an SUV of less than 1.9, and therefore lesions were divided into high (≥ 1.9) and low ( < 1.9) SUV groups. The sensitivity of PET for correctly diagnosing malignancy was 100% with a specificity of 76.9% and an overall accuracy of 83.0%, indicating that the SUV may be a useful parameter for differentiating malignant tumours (Table IV) . It should, however, be noted that some benign lesions such as giant-cell tumour (GCT) of the tendon sheath (case 21), an elastofibroma (case 26), an abscess (case 27), osteomyelitis (case 5) and neurogenic benign tumours (cases 23, 25 and 28) had high SUVs.
Thirteen lesions were examined by both FMT-and FDG-PET with less than two weeks between studies. Two malignant tumours had an SUV of FMT higher than 1.3, while in all the benign lesions it was less than 1.3. Two benign lesions in the FDG-PET high group, a xanthofibroma and a schwannoma, were in the low group in the FMT-PET group.
Metastatic lesions of bone had particularly high SUVs (Table I) with FDG-PET, suggesting that there was a relationship between uptake of FDG and metastatic progression. We therefore calculated the SUVs in the metastatic lesions related to bone and soft-tissue malignancies (Table III) . The mean SUV in metastatic lesions was significantly higher than that in primary sarcomas (Table V) .
Because of suspicion of malignancy, biopsy or primary wide resection was performed as a first step for all lesions with an SUV of 1.9 or above, except for a chondrosarcoma (case 9) and a schwannoma (case 28). Early in our study we speculated that the cut-off for malignancies should be 2.0 according to an early report, 27 but the chondrosarcoma occurring in the periosteal region and which resembled a periosteal chondroma (case 9) had an SUV of 1.9. We therefore incorrectly selected marginal resection for the first operation. Thereafter, we set a cut-off SUV value of 1.9 for malignancies, and biopsy or primary wide resection was chosen as a first step for lesions with an SUV of 1.9 or above. However, wide resection was performed for a patient (case 25) having a schwannoma in the thigh because the SUV was 3.3. Fortunately, only a minor sensory defect was left after the operation. We also noted that the SUV of neurogenic benign tumours including schwannomas and neurofibromas varied widely between 0.1 (case 53) and 3.7 (case 23). On the basis of these results and CT and MRI findings, marginal resection/enucleation was successfully used in another patient with a schwannoma (case 28) in spite of the SUV of 2.8. In cases in which the SUV was lower than 1.9, marginal resection or curettage was applied, although biopsies were taken from two benign lesions (cases 15 and 48).
To investigate the linkage between expression of PHI and uptake of FDG we chose the benign neurogenic tumours. Five out of seven such lesions were available for this investigation and RNA was successfully obtained from samples with an SUV of 3.3 (case 25), 1.7 (case 34) and 1.0 (case 42). In the other two RNA degradation was severe. As shown in Figure 4 , an RT-PCR product with a size of 1700 bp was found in only the sample with a high SUV (case 25). We also tried to extract RNA from bone metastases but, unfortunately, all had degradation.
Discussion
The high glycolytic rate of various neoplasia facilitates imaging with glucose analogues such as FDG and PET. 4 The rates of glucose uptake in sarcomas are known to be high. 28 The average dose-uptake ratio (DUR) which is semiquantitative and weight-dependent, is obtained from the FDG image and can distinguish between the presence and absence of malignancy. 9, 15 The metabolic rate of glucose can distinguish between sarcomas of low, intermediate, and high grades as defined by the grading system for soft-tissue sarcomas. 10, 11 Recently, quantitative determination has shown that the FDG metabolic rate of the tumour correlates with the grade of sarcoma but not with S-phase percentage or aneuploidy. 29 uptake of FDG in malignant tumours, especially in metastatic lesions, was greatly increased, but no abnormal accumulation was observed in the scars after excision of two malignant tumours (cases 54 and 52; Table II) . By contrast, recurrent liposarcoma has been found to be clearly depicted by FDG-PET imaging. 13 In our study a recurrent liposarcoma (case 24) showed high uptake of FDG while little accumulation was observed in the area of the scars (Fig. 2) . This was also observed with a recurrent desmoid tumour (case 46). These findings indicate the possibility of differentiating scars from recurrences of tumour. Thus this approach may be useful for preoperative detection and also for postoperative monitoring of local and metastatic recurrence. In our study, there was a highly significant difference (p < 0.0001) in the SUV between benign and malignant lesions. Dehdashti et al 27 demonstrated that a cut-off value of 2.0 for SUV could distinguish benign from malignant intraosseous lesions. In our study, when the cut-off value was set at 1.9, the sensitivity for correctly diagnosing malignancy was 100% with a specificity of 76.9% and an overall accuracy of 83.0%. Therefore, since the cell type of the lesion is unknown in preoperative planning, SUV may give useful information for differentiating malignant tumours from benign lesions in the musculoskeletal system. For example, haemangiomas grow slowly, show calcification in plain radiographs and demonstrate heterogeneous features in MRI with gadolinium enhancement. 31 Synovial sarcomas, however, also grow slowly, over 20 years in some cases, 32 and show calcification and similar MRI findings. It can sometimes be difficult to distinguish between the two. It is therefore of interest that in our study the SUV of all haemangiomas was under 1.4, while that of synovial sarcoma was 2.0.
With the SUV to a cut-off as the criterion, wide resection was performed for three benign lesions including a GCT of the tendon sheath, a schwannoma and an abscess. A high uptake of FDG has been reported for infectious foci with a ring appearance, as also observed in our case, and thus may aid the differential diagnosis. 9, 33 On the other hand, for neurogenic benign tumours, major operations run the risk of damage to motor functions but, fortunately, in this patient (case 25) only a minor sensory defect remained. Even biopsies may present some risk. Although qualitative investigations such as CT and MRI may help in the selection of an appropriate operation, as shown in case 28, other quantitative analyses using additional positron-emitters in combination are required, especially when Tinel's sign is absent. Recently, we have developed FMT as a tumourdetecting amino-acid tracer for PET imaging, 23 which has clearly shown a clinical application for the detection of brain tumours. 34 In our study, FMT-PET distinguished malignant tumours from benign lesions, and two falsepositive benign lesions estimated by FDG-PET were evaluated correctly as the low group in FMT. It may therefore be an additional agent for evaluating such benign lesions. In the diagnosis of musculoskeletal tumours it is sometimes difficult to exclude osteomyelitis. Unexpectedly, however, in one patient (case 5) a high uptake of FDG (SUV, 3.22) was found. Recently, it has been shown that FDG-PET has been highly accurate and superior to immunoscintigraphy with 99m Tc-labelled monoclonal antigranulocyte antibodies for the detection of chronic osteomyelitis. 35 Active foci of infection have been reported to show a high SUV in FDG-PET imaging, 27, 36 and FDG-PET imaging for the assessment of head and neck squamous-cell carcinoma recorded abnormal uptake of tracer in a case of mandibular osteomyelitis which was unrelated to malignancy. 37 FDG-PET imaging may thus not be reliable for the differentiation between skeletal malignancy and osteomyelitis. Other quantitative analyses using additional positron-emitters such as 99m
Tc-labelled monoclonal antigranulocyte antibodies or FMT are required for the exclusion of osteomyelitis.
In our study, metastatic lesions of bone had higher SUVs. Recently, FDG uptake was shown to be related to prognosis in patients with pancreatic adenocarcinoma. 8 The rate of accumulation of FDG may thus be associated with metastatic progression of neoplastic cells. This is confirmed by the finding that SUV of pulmonary metastases of osteogenic sarcoma was higher than that of primary osteogenic sarcoma, as observed in the literature. 9, 15 In preoperative planning, this may provide valuable information. As shown in Figure 3 , for example, accumulation was detected in the femur on 99m
Tc methylene diphosphonate bone scintigraphy during postoperative periodic inspection after resection of breast cancer. Intralesional sclerotic changes were observed on plain radiography in the corresponding area. Since bone formation is often observed in metastases of breast cancer, 38 bone metastasis was strongly suspected.
The SUV, however, was 0.9 suggesting a benign lesion, and curettage was then correctly applied on the basis of a diagnosis of enchondroma. Haberkorn et al 39 reported that the uptake of FDG is related to differences in the transcription of glycolysisassociated genes. Among the products are glucose transporter as a glucose inward flux regulator, 7 hexokinase (HK) as a part of increased glycolysis, 40 and glucose-6-phosphatase as a scavenger of HK products. 16 Our finding of higher uptake in metastatic lesions suggests that metastasis-associated molecules may play a role. PHI, which is located just after HK in the chain of glycolytic metabolism, has recently * lesions were divided into high (≥ 1.9) and low (< 1.9) SUV groups PHI mRNA expression by RT-PCR. Total cellular RNA was isolated from samples of three benign neurogenic tumours (cases 25, 34 and 42). The RNA messages of PHI/AMF and S14 ribosomal protein (S14 RP) as an internal control were amplified, and analysed in a 1% agarose gel. The SUVs are given below.
been found to be related to metastatic progression. 20, 41 Our
RT-PCR analysis showed that mRNA signals for PHI were only elevated in benign neurogenic tumours with a high uptake of FDG. The oligonucleotide primers for PCR used here were designed to cover the PHI open reading frame and no sequence abnormalities have been found in metastatic cells. 20 Although our examination was preliminary, the present results suggest that PHI expression may also be associated, at least in part, with uptake of FDG, presumably as a contributor to enhanced glycolysis.
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